Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Recher

Showing results (471-480 of 488) with videos related to

Pageof 49
Sort By:
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Leukemia|June 11, 2004
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemiaC Terre, V Eclache, P Rousselot, et al.
American Journal of Hematology|February 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World StudyGaspar Aspas Requena, Pau Montesinos, Emilie Bérard, et al.
The Journal of Experimental Medicine|June 16, 2010
Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiencyJolan E Walter, Francesca Rucci, Laura Patrizi, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Blood|February 4, 2012
B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in miceMike Recher, Siobhan O Burns, Miguel A de la Fuente, et al.
Leukemia|March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemiaJustine Decroocq, Rudy Birsen, Camille Montersino, et al.
The Journal of Allergy and Clinical Immunology|January 18, 2015
Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiencyClaudia Wehr, Andrew R Gennery, Caroline Lindemans, et al.
Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 49

Showing results (471-480 of 488) with videos related to

Sort By:
Pageof 49
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Leukemia|June 11, 2004
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemiaC Terre, V Eclache, P Rousselot, et al.
American Journal of Hematology|February 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World StudyGaspar Aspas Requena, Pau Montesinos, Emilie Bérard, et al.
The Journal of Experimental Medicine|June 16, 2010
Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiencyJolan E Walter, Francesca Rucci, Laura Patrizi, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Blood|February 4, 2012
B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in miceMike Recher, Siobhan O Burns, Miguel A de la Fuente, et al.
Leukemia|March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemiaJustine Decroocq, Rudy Birsen, Camille Montersino, et al.
The Journal of Allergy and Clinical Immunology|January 18, 2015
Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiencyClaudia Wehr, Andrew R Gennery, Caroline Lindemans, et al.
Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 49